Scientists are beginning to unlock powerful new ways to fight cancer by designing bioengineered molecules that can both destroy tumors and activate the immune system. One of the most promising breakthroughs has come from Virginia Commonwealth University, where researchers are targeting glioblastoma, a deadly brain cancer that resists nearly every current form of treatment.<\/p>\n\n\n\n
Led by Paul B. Fisher, MPh, Ph.D., FNAI, and Swadesh K. Das, Ph.D., the team at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine has created a therapy they call the Fusion Superkine, or FSK. In their words, it is a therapy that \u201crepresents a distinctive platform for immune-gene therapy that not only eradicates tumor cells but also boosts localized immune activity, resulting in prolonged effects.\u201d<\/p>\n\n\n\n
Glioblastoma has remained one of the toughest cancers to treat because it grows quickly, spreads deeply into the brain, and creates what scientists describe as a \u201ccold\u201d tumor environment. This environment not only shields the cancer from the immune system but also blocks drugs from working. Even after surgery, chemotherapy, or radiation, more than 90 percent of patients see the cancer return within six to nine months, and it often comes back even stronger. \u201cWe\u2019re aiming for the \u2018holy grail;\u2019 a cure for this devastating cancer,\u201d Fisher explained.<\/p>\n\n\n\n
The Fusion Superkine is unique because it combines two powerful molecules into one. The first, IL-24S, is a next-generation form of the melanoma differentiation associated gene-7\/interleukin-24, known as a \u201cSuperkine.\u201d It has improved stability and is able to trigger cancer-selective cell death. The second component, IL-15, is a cytokine that strengthens the immune system by activating natural killer cells and T cells.<\/p>\n\n\n\n
By combining the two into a single molecule, researchers created what they call a one-two punch: direct destruction of cancer cells along with an immune system that is reawakened to keep attacking. In animal tests, the Fusion Superkine was more effective than either IL-24S or IL-15 alone. Tumors shrank significantly, and survival rates improved. As Fisher summarized, \u201cThis is the tip of the iceberg.\u201d<\/p>\n\n\n\n
Treating brain cancer also presents another major challenge: the blood-brain barrier. This natural defense system keeps harmful substances out of the brain, but it also blocks most drugs. To solve this, the team at VCU used a method called FUS-DMB, which stands for focused ultrasound with double microbubbles. This technique uses sound waves and tiny bubbles to gently open the blood-brain barrier, allowing the Fusion Superkine to pass through safely.<\/p>\n\n\n\n
The therapy is carried into the brain using a type 5 adenovirus vector. According to Fisher, this viral delivery system \u201cpermits safe and effective targeted delivery through the blood-brain barrier into the brain.\u201d A peer reviewer of the study called this method \u201ca groundbreaking advancement,\u201d noting that it could be applied not only to brain cancer but also to many other forms of gene and virus-based therapies.<\/p>\n\n\n\n
The implications of this work may go well beyond glioblastoma. Because the delivery system can be adapted to other tissues, it could potentially treat cancers in organs that are difficult to reach or tumors that spread into the brain from elsewhere. One reviewer of the study wrote, \u201cThe engineering and successful testing of an adenoviral vector capable of simultaneously delivering two distinct cytokines represent a significant milestone.\u201d Clinical trials in humans are already being planned, with a brain cancer study expected to begin in 2026. Fisher believes the long-term goal is clear: \u201cIn the future we may be able to treat both primary brain tumors and secondary brain tumors non-invasively without surgery.\u201d<\/p>\n\n\n\n
While the Fusion Superkine offers a bold new way to attack brain tumors, other scientists are tackling how cancers manage to suppress the immune system in the first place. At Purdue University, Professor W. Andy Tao and his colleagues have developed a system to study how tumor-derived extracellular vesicles (EVs) interfere with immune cells. These vesicles carry cargo such as RNA-binding proteins that can weaken immune responses and compromise treatments like immunotherapy.<\/p>\n\n\n\n
\u201cRNA-binding proteins are important since proteins typically do major work for the function of cells,\u201d Tao explained. By labeling RNA molecules with synthetic organic tags that respond to ultraviolet light, his team was able to map how these RNAs interact with proteins inside immune cells. In experiments with leukemia and rare liver cancer cells, the method proved effective in identifying large numbers of proteins that may play a role in cancer\u2019s ability to resist immune attack. \u201cThe role of the EV is certainly being recognized more and more,\u201d Tao said.<\/p>\n\n\n\n
Another promising line of research is coming from Stanford University, where a team led by Jennifer Cochran, Ronald Levy, and Idit Sagiv-Barfi has designed a synthetic molecule called PIP-CpG. This molecule combines a tumor-targeting peptide, PIP, with an immune-activating agent, CpG. When injected intravenously, it travels through the bloodstream, attaches directly to cancer cells, and stimulates the immune system to attack.<\/p>\n\n\n\n
In animal studies, the results were striking. Mice with aggressive breast cancer responded strongly to the therapy, and some were completely cured after only a few doses. \u201cWe essentially cured some animals with just a few injections,\u201d Cochran said. \u201cIt was pretty astonishing.\u201d In several cases, the treatment not only eliminated tumors but also prevented them from coming back.<\/p>\n\n\n\n
Levy emphasized how powerful the therapy\u2019s design could be: \u201cThe sculpting of the tumor microenvironment by this intravenously administered molecule was identical to injecting immune-stimulating agents directly into the tumor.\u201d This is important because many tumors cannot be injected safely, and systemic delivery of immune stimulants has rarely worked well before.<\/p>\n\n\n\n
These advances point to a new era in cancer therapy\u2014one where direct tumor killing is combined with a strengthened immune response, and delivery methods are tailored to bypass the body\u2019s natural barriers. The Fusion Superkine is moving toward clinical trials, Purdue\u2019s method is giving scientists better insight into how tumors disable immunity, and Stanford\u2019s PIP-CpG has shown real promise in hard-to-treat cancers like breast and pancreatic tumors.<\/p>\n\n\n\n
Each of these approaches shares a common goal: making cancer visible to the immune system and ensuring the body can fight back long after the initial tumor is gone. As Fisher noted, the hope is not just treatment but lasting cures. Cochran reflected on the progress at Stanford by saying, \u201cAfter more than 10 years of work on PIP, it is rewarding to experience this convergence of expertise.\u201d<\/p>\n\n\n\n
While challenges remain, the excitement is growing. These bioengineered molecules show that by combining precision design with the body\u2019s natural defenses, the dream of curing cancer may be closer than ever before.<\/p>\n\n\n\n
HNZ Editor: <\/strong> We suspect that these advances are a direct result of artificial intelligence involvement in research. Expect this kind of research to accelerate, these are good times for health research.<\/p>\n","protected":false},"excerpt":{"rendered":" Scientists are beginning to unlock powerful new ways to fight cancer by designing bioengineered molecules that can both destroy tumors and activate the immune system. One of the most promising breakthroughs has come from Virginia Commonwealth University, where researchers are targeting glioblastoma, a deadly brain cancer that resists nearly every current form of treatment. Led by Paul B. Fisher, MPh, Ph.D., FNAI, and Swadesh K. Das, Ph.D., the team at VCU Massey Comprehensive Cancer Center and the VCU Institute of […]<\/p>\n","protected":false},"author":2,"featured_media":7038,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-7037","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-research"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7037"}],"version-history":[{"count":1,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7037\/revisions"}],"predecessor-version":[{"id":7039,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/7037\/revisions\/7039"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/media\/7038"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}